Drugs / LYN-005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05779241 | Apr → Nov 2023 | schizoaffective disorder, schizophrenia | Lyndra Inc. | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04567524 Comparator | Aug → Dec 2020 | schizophrenia | Lyndra Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYN-005 | “Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone.” NCT05779241 ↗ |
| Route | Oral | “oral, extended release (ER) formulation” NCT04567524 ↗ |